Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 16, Issue 4, Pages 543-547Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2009.11.021
Keywords
Prolymphocytic leukemia; Allogeneic stem cell transplantation
Categories
Funding
- NCI NIH HHS [U24 CA076518-12, U24 CA76518, U24 CA076518] Funding Source: Medline
- NHLBI NIH HHS [5U01HL069294, U01 HL069294] Funding Source: Medline
Ask authors/readers for more resources
The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to case-reports and small case series. We reviewed the database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL. We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of 13 months, progression-free survival (PFS) was 33% (95% confidence interval [CI] 20%-47%) at 1 year. The most common cause of death was relapse or progression in 49%. The cumulative incidence of treatment-related mortality (TRM) at I-year posttransplant was 28%. The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of a larger population of patients is needed to determine which patients are more likely to benefit. Biol Blood Marrow Transplant 16: 543-547 (2010) (C) 2010 American Society for Blood Marrow Transplantation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available